Investor Relations

Corporate Profile

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Change

Volume

52 Week High

52 Week Low

May 12, 2021 10:57 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 10, 2021

FOSTER CITY, Calif. --(BUSINESS WIRE)--May 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 10, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 87,500 shares of common stock to 9

Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

May 6, 2021

- NDA for maralixibat in Alagille syndrome (ALGS) granted priority review by U.S. FDA; PDUFA date is September 29, 2021 - Received additional $65.0 million in funding from Oberland Capital based on NDA acceptance - Commercial team hired in anticipation of U.S.

Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021

April 29, 2021

FOSTER CITY, Calif. --(BUSINESS WIRE)--Apr. 29, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced that the company will report financial results for the quarter ended March 31, 2021 on Thursday, May 6, 2021 . That same day, Mirum will host a conference call and audio webcast at

Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases

April 29, 2021

- CANbridge to lead development and commercialization in China ; expands rare disease pipeline - Mirum is entitled to receive up to an aggregate of $120.0 million in upfront and milestone payments, and significant double-digit tiered royalties FOSTER CITY, Calif. & BEIJING --(BUSINESS WIRE)--Apr.

Events

Q1 2021 Financial Results Conference Call

May 6, 2021 at 4:30 PM EDT

Click here for Webcast

Oppenheimer 31st Annual Healthcare Conference

Mar 17, 2021 at 3:50 PM EDT

H.C. Wainwright Global Life Sciences Conference

Mar 9, 2021

Investor Relations

Investor Relations

Corporate Profile

Header Menu